IDEXX Laboratories reported strong Q3 results with 9.86% organic revenue growth, 13.4% operating income growth, and 17.9% EPS growth, exceeding market expectations. The company raised its full-year revenue and EPS guidance, driven by its best-in-class diagnostics, recurring revenue, and innovation pipeline. The recent acquisition of CoVet adds AI-driven workflow software, enhancing customer retention and cross-selling opportunities. Despite premium valuation, IDEXX's durable competitive advantages and strong free cash flow support a multi-year growth outlook.
IDEXX Laboratories shares have seen a modest increase, trading at USD 677.00 with a 1-day gain of 0.74% on Pluang. The stock's market cap stands at $52.94 billion, reflecting steady investor interest. These figures are current as of Nov 04, 2026 18:11 WIB.
